Login to Your Account

Acorda launches pivotal study to tackle ‘off’ episodes in Parkinson’s

By Jennifer Boggs
Managing Editor

Wednesday, December 10, 2014

Acorda wasted no time getting down to business following its buyout of Civitas Therapeutics Inc. in October, enrolling the first patient in the pivotal study of CVT-301, an inhaled version of levodopa designed specifically to reduce motor fluctuation – i.e., “off” episodes – in Parkinson’s disease patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription